Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales

Reuters

Nov 05

Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales

Overview

Geron Q3 2025 revenue rises to $47.2 mln, driven by RYTELO sales
Net loss for Q3 2025 narrows to $18.4 mln from $26.4 mln in 2024
Operating income for Q3 2025 beats analyst expectations

Outlook

Company expects 2025 operating expenses between $250 mln and $260 mln
Company anticipates IMpactMF interim analysis in H2 2026
Geron believes existing resources and RYTELO sales will fund future operations

Result Drivers

RYTELO SALES - Achieved $47.2 mln in net product revenue for Q3 2025, despite a 3% decline in demand

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Product Revenue		$47.16 mln
Q3 EPS		-$0.03
Q3 Net Income		-$18.42 mln
Q3 Operating Income	Beat	-$13.88 mln	-$17.30 mln (7 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and 1 "sell" or "strong sell"
Wall Street's median 12-month price target for Geron Corp is $4.00, about 71.3% above its November 4 closing price of $1.15

Press Release: ID:nBw2h2mvSa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2581721266"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2581721266\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2581721266?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-05 20:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581721266","market":"fut","top_or_hot":-1,"title":"Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales </title></head><body><p><span>Overview</span></p><ul><li><p>Geron Q3 2025 revenue rises to $47.2 mln, driven by RYTELO sales</p></li><li><p>Net loss for Q3 2025 narrows to $18.4 mln from $26.4 mln in 2024</p></li><li><p>Operating income for Q3 2025 beats analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects 2025 operating expenses between $250 mln and $260 mln</p></li><li><p>Company anticipates IMpactMF interim analysis in H2 2026</p></li><li><p>Geron believes existing resources and RYTELO sales will fund future operations</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>RYTELO SALES - Achieved $47.2 mln in net product revenue for Q3 2025, despite a 3% decline in demand</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Product Revenue</p></td><td></td><td><p>$47.16 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.03</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$18.42 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td><p>Beat</p></td><td><p>-$13.88 mln</p></td><td><p>-$17.30 mln (7 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 2 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Geron Corp is $4.00, about 71.3% above its November 4 closing price of $1.15</p></li></ul><p>Press Release: <span>ID:nBw2h2mvSa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-05 20:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales </title></head><body><p><span>Overview</span></p><ul><li><p>Geron Q3 2025 revenue rises to $47.2 mln, driven by RYTELO sales</p></li><li><p>Net loss for Q3 2025 narrows to $18.4 mln from $26.4 mln in 2024</p></li><li><p>Operating income for Q3 2025 beats analyst expectations</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects 2025 operating expenses between $250 mln and $260 mln</p></li><li><p>Company anticipates IMpactMF interim analysis in H2 2026</p></li><li><p>Geron believes existing resources and RYTELO sales will fund future operations</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>RYTELO SALES - Achieved $47.2 mln in net product revenue for Q3 2025, despite a 3% decline in demand</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Product Revenue</p></td><td></td><td><p>$47.16 mln</p></td><td></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.03</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$18.42 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td><p>Beat</p></td><td><p>-$13.88 mln</p></td><td><p>-$17.30 mln (7 Analysts)</p></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 2 \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>Wall Street's median 12-month price target for Geron Corp is $4.00, about 71.3% above its November 4 closing price of $1.15</p></li></ul><p>Press Release: <span>ID:nBw2h2mvSa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GERN","symbol_name":"杰龙","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH0KN:1","article_id":"2581721266","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581721266","pubTimestamp":1762344501,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO salesOverviewGeron Q3 2025 revenue rises to $47.2 mln, driven by RYTELO salesNet loss for Q3 2025 narrows to $18.4 mln fro","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"GERN":"杰龙","BK4139":"生物科技"},"translate_title":"血液学药物开发商Geron Q3净亏损收窄，受RYTELO销售推动","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GERN":0.9},"content_text":"Hematology drug developer Geron Q3 narrows net loss narrows, driven by RYTELO sales OverviewGeron Q3 2025 revenue rises to $47.2 mln, driven by RYTELO salesNet loss for Q3 2025 narrows to $18.4 mln from $26.4 mln in 2024Operating income for Q3 2025 beats analyst expectationsOutlookCompany expects 2025 operating expenses between $250 mln and $260 mlnCompany anticipates IMpactMF interim analysis in H2 2026Geron believes existing resources and RYTELO sales will fund future operationsResult DriversRYTELO SALES - Achieved $47.2 mln in net product revenue for Q3 2025, despite a 3% decline in demandKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Product Revenue$47.16 mlnQ3 EPS-$0.03Q3 Net Income-$18.42 mlnQ3 Operating IncomeBeat-$13.88 mln-$17.30 mln (7 Analysts)Analyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 6 \"strong buy\" or \"buy\", 2 \"hold\" and 1 \"sell\" or \"strong sell\"Wall Street's median 12-month price target for Geron Corp is $4.00, about 71.3% above its November 4 closing price of $1.15Press Release: ID:nBw2h2mvSaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}